))
CAR-T therapies: Faster, better, cheaper
Manage episode 452092504 series 3079777
Innehåll tillhandahållet av pharmaphorum. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av pharmaphorum eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Working in the in vivo cell therapy space, Johnson discusses the injection of a manufactured vector into a patient to create the CAR-T cells directly inside the body of the patient, without the need for chemotherapy treatment beforehand – hence such hope for in vivo cell therapy’s potential. Targeting both T-cells and NK-cells, Johnson notes that this is a distinguishing factor of the work Interius does.
On the CAR-T space generally, Comstock and Johnson explore its evolution and how these products can be made faster, better, and cheaper – including the democratisation of these therapies, and the accessibility gains this means for patients.
219 episoder
Dela
